Steven N Goodman

List of Publications by Year
in descending order

136 papers	22,561 citations	30551 56 h-index	15253 130 g-index
148 all docs	148 docs citations	148 times ranked	32777 citing authors

#	Article	IF	Citations
1	How large should the next study be? Predictive power and sample size requirements for replication studies. Statistics in Medicine, 2022, 41, 3090-3101.	0.8	10
2	The Role of Masks in Mitigating the SARS-CoV-2 Pandemic: Another Piece of the Puzzle. Annals of Internal Medicine, 2021, 174, 419-420.	2.0	13
3	Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1185.	3.8	209
4	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	5.8	194
5	Randomized COVID-19 vaccination rollout can offer direct real-world evidence. Journal of Clinical Epidemiology, 2021, 138, 199-202.	2.4	5
6	Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19. JAMA Network Open, 2021, 4, e2111417.	2.8	460
7	U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013â€“2018. Annals of Internal Medicine, 2021, 174, 1603-1611.	2.0	10
8	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
9	Calibrating the Scientific Ecosystem Through Meta-Research. Annual Review of Statistics and Its Application, 2020, 7, 11-37.	4.1	48
10	Association of Rapid Eye Movement Sleep With Mortality in Middle-aged and Older Adults. JAMA Neurology, 2020, 77, 1241.	4.5	55
11	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. Annals of Internal Medicine, 2020, 172, 35.	2.0	203
12	COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance. Annals of Internal Medicine, 2020, 173, 652-653.	2.0	20
13	Preprint Serversâ€™ Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations. JAMA - Journal of the American Medical Association, 2020, 324, 1901.	3.8	40
14	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research, 2020, 9, 1193.	0.8	41
15	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research, 2020, 9, 1193.	0.8	38
16	How often do leading biomedical journals use statistical experts to evaluate statistical methods? The results of a survey. PLoS ONE, 2020, 15, e0239598.	1.1	32
17	Title is missing!. , 2020, 15, e0239598.		0
18	Title is missing!. , 2020, 15, e0239598.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0239598.		0
20	Title is missing!. , 2020, 15, e0239598.		0
21	Harms From Uninformative Clinical Trials. JAMA - Journal of the American Medical Association, 2019, 322, 813.	3.8	70
22	Random-Effects Assumption in Meta-analysesâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 322, 82.	3.8	0
23	Should Psychology Journals Adopt Specialized Statistical Review?. Advances in Methods and Practices in Psychological Science, 2019, 2, 240-249.	5.4	9
24	The high resource impact of reformatting requirements for scientific papers. PLoS ONE, 2019, 14, e0223976.	1.1	13
25	Why is Getting Rid of P-Values So Hard? Musings on Science and Statistics. American Statistician, 2019, 73, 26-30.	0.9	37
26	Urodynamic factors associated with the large capacity bladder and incomplete emptying after prolapse repair (2009â€2015). Neurourology and Urodynamics, 2019, 38, 1322-1331.	0.8	4
27	Lost Evidence From Registered Large Long-Unpublished Randomized Controlled Trials: A Survey. Annals of Internal Medicine, 2019, 171, 300.	2.0	14
28	Random-Effects Meta-analysis. JAMA - Journal of the American Medical Association, 2019, 321, 301.	3.8	103
29	Lack of Diagnostic Utility of â€œAmino Acid Dysregulation Metabotypesâ€. Biological Psychiatry, 2019, 85, e41-e42.	0.7	2
30	Redefine statistical significance. Nature Human Behaviour, 2018, 2, 6-10.	6.2	1,763
31	2007 The clinical research operations program: Educating clinical research staff. Journal of Clinical and Translational Science, 2018, 2, 61-61.	0.3	0
32	Machine Learning, Health Disparities, and Causal Reasoning. Annals of Internal Medicine, 2018, 169, 883.	2.0	40
33	How sure are you of your result? Put a number on it. Nature, 2018, 564, 7-7.	13.7	15
34	Inappropriate Statistical Analysis and Reporting in Medical Research: Perverse Incentives and Institutional Solutions. Annals of Internal Medicine, 2018, 169, 577.	2.0	15
35	Annals Understanding Clinical Research: Interpreting Results With Large P Values. Annals of Internal Medicine, 2018, 169, 485-486.	2.0	5
36	How and why studies disagree about the effects of education on health: A systematic review and meta-analysis of studies of compulsory schooling laws. Social Science and Medicine, 2018, 212, 168-178.	1.8	106

#	Article	IF	Citations
37	Statistical Code to Support the Scientific Story. Annals of Internal Medicine, 2018, 168, 828-829.	2.0	15
38	Assessing scientists for hiring, promotion, and tenure. PLoS Biology, 2018, 16, e2004089.	2.6	244
39	Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research. JAMA - Journal of the American Medical Association, 2017, 317, 705.	3.8	58
40	Sharing Clinical Research Dataâ€"Finding the Right Balance. JAMA Internal Medicine, 2017, 177, 1241.	2.6	2
41	Posing Causal Questions When Analyzing Observational Dataâ€"Reply. JAMA - Journal of the American Medical Association, 2017, 318, 201.	3.8	0
42	Using big data analytics to extract disease surveillance information from point of care diagnostic machines. Pervasive and Mobile Computing, 2017, 42, 470-486.	2.1	23
43	Five ways to fix statistics. Nature, 2017, 551, 557-559.	13.7	86
44	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European Journal of Epidemiology, 2016, 31, 337-350.	2.5	1,761
45	What does research reproducibility mean?. Science Translational Medicine, 2016, 8, 341ps12.	5.8	804
46	Quantifying over-estimation in early stopped clinical trials and the â€œfreezing effectâ€•on subsequent research. Clinical Trials, 2016, 13, 621-631.	0.7	27
47	Aligning statistical and scientific reasoning. Science, 2016, 352, 1180-1181.	6.0	75
48	Meta-research: Evaluation and Improvement of Research Methods and Practices. PLoS Biology, 2015, 13, e1002264.	2.6	202
49	Data monitoring committees for pragmatic clinical trials. Clinical Trials, 2015, 12, 530-536.	0.7	32
50	Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2015, 21, 30-38.	3.2	158
51	Clinical Trial Data Sharing: What Do We Do Now?. Annals of Internal Medicine, 2015, 162, 308.	2.0	7
52	Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. Biostatistics, 2014, 15, 23-27.	0.9	12
53	Opening the FDA Black Box. JAMA - Journal of the American Medical Association, 2014, 311, 361.	3.8	9
54	Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change. Annals of Internal Medicine, 2014, 160, 267-270.	2.0	344

#	Article	IF	Citations
55	Causal Inference in Public Health. Annual Review of Public Health, 2013, 34, 61-75.	7.6	251
56	The Researchâ€Treatment Distinction: A Problematic Approach for Determining Which Activities Should Have Ethical Oversight. Hastings Center Report, 2013, 43, S4-S15.	0.7	203
57	An Ethics Framework for a Learning Health Care System: A Departure from Traditional Research Ethics and Clinical Ethics. Hastings Center Report, 2013, 43, S16-27.	0.7	420
58	Raw data from clinical trials: within reach?. Trends in Pharmacological Sciences, 2013, 34, 645-647.	4.0	57
59	A decade of Clinical Trials. Clinical Trials, 2013, 10, 837-839.	0.7	0
60	Advances in Regulatory Science at the Food and Drug Administration. JAMA - Journal of the American Medical Association, 2013, 309, 2103.	3.8	9
61	Bayesian Methods for Evidence Evaluation. Circulation, 2013, 127, 2367-2369.	1.6	5
62	Closing in on the Truth About Recombinant Human Bone Morphogenetic Protein-2: Evidence Synthesis, Data Sharing, Peer Review, and Reproducible Research. Annals of Internal Medicine, 2013, 158, 916.	2.0	18
63	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. PLoS ONE, 2013, 8, e68966.	1.1	31
64	All That Glitters Isn't Gold: A Survey on Acknowledgment of Limitations in Biomedical Studies. PLoS ONE, 2013, 8, e73623.	1.1	14
65	Ethical Considerations in Studying Drug Safety â€" The Institute of Medicine Report. New England Journal of Medicine, 2012, 367, 959-964.	13.9	21
66	Quasi-random reflections on randomized controlled trials and comparative effectiveness research. Clinical Trials, 2012, 9, 22-26.	0.7	9
67	The Methods of Comparative Effectiveness Research. Annual Review of Public Health, 2012, 33, 425-445.	7.6	139
68	An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA. Clinical Cancer Research, 2011, 17, 4494-4503.	3.2	126
69	Analysis of Subgroup Effects in Randomized Trials When Subgroup Membership is Missing: Application to the Second Multicenter Automatic Defibrillator Intervention Trial. Journal of the Royal Statistical Society Series C: Applied Statistics, 2011, 60, 607-617.	0.5	3
70	Diastolic Blood Pressure Levels and Ischemic Stroke Incidence in Older Adults With White Matter Lesions. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 74-81.	1.7	11
71	Landmark clinical trials: a new journal series. Clinical Trials, 2011, 8, 128-128.	0.7	0
72	Confessions of a chagrined trialist. BMJ Quality and Safety, 2011, 20, i97-i98.	1.8	4

#	Article	IF	Citations
73	Harry Marks: an appreciation. Clinical Trials, 2011, 8, 123-127.	0.7	1
74	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood, 2010, 115, 2136-2141.	0.6	107
75	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood, 2010, 115, 3224-3230.	0.6	346
76	Commentary. Biostatistics, 2010, 11, 389-390.	0.9	2
77	Bias and Trials Stopped Early for Benefit. JAMA - Journal of the American Medical Association, 2010, 304, 156.	3.8	17
78	On making clinical trials possible. Clinical Trials, 2010, 7, 621-621.	0.7	1
79	Building a Bayesian Bridge From Evidence to Guidelines. Archives of Internal Medicine, 2009, 169, 1436.	4.3	7
80	Considering Usual Medical Care in Clinical Trial Design. PLoS Medicine, 2009, 6, e1000111.	3.9	54
81	Stopping trials for efficacy: an almost unbiased view. Clinical Trials, 2009, 6, 133-135.	0.7	18
82	Sensitive digital quantification of DNA methylation in clinical samples. Nature Biotechnology, 2009, 27, 858-863.	9.4	317
83	A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia, 2009, 50, 322-325.	2.6	126
84	Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning. Biology of Blood and Marrow Transplantation, 2009, 15, 242-248.	2.0	64
85	Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change. Annals of Internal Medicine, 2009, 151, 206.	2.0	293
86	An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB: Ethics & Human Research, 2009, 31, 1-10.	0.8	34
87	Circulating mutant DNA to assess tumor dynamics. Nature Medicine, 2008, 14, 985-990.	15.2	2,207
88	Systematic reviews are not biased by results from trials stopped early for benefit. Journal of Clinical Epidemiology, 2008, 61, 95-96.	2.4	16
89	A Dirty Dozen: Twelve P-Value Misconceptions. Seminars in Hematology, 2008, 45, 135-140.	1.8	459
90	Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer. Journal of Urology, 2008, 179, 743-747.	0.2	48

#	Article	IF	Citations
91	RNAi-Mediated Silencing of Nuclear Factor Erythroid-2â€“Related Factor 2 Gene Expression in Nonâ€“Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy. Cancer Research, 2008, 68, 7975-7984.	0.4	331
92	Purpose and Benefits of Early Phase Cancer Trials: What Do Oncologists Say? What Do Patients Hear?. Journal of Empirical Research on Human Research Ethics, 2008, 3, 57-68.	0.6	51
93	Rashomon revisited: two views of monitoring the Women's Health Initiative trials. Clinical Trials, 2007, 4, 205-206.	0.7	2
94	Reproducible Research: Moving toward Research the Public Can Really Trust. Annals of Internal Medicine, 2007, 146, 450.	2.0	191
95	Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials. Annals of Internal Medicine, 2007, 146, 882.	2.0	53
96	Disclosure of Individual Surgeon's Performance Rates During Informed Consent. Annals of Surgery, 2007, 245, 507-513.	2.1	36
97	Why Most Published Research Findings Are False: Problems in the Analysis. PLoS Medicine, 2007, 4, e168.	3.9	70
98	Ethical Issues in Evidence-Based Surgery. Surgical Clinics of North America, 2006, 86, 151-168.	0.5	21
99	Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. The Cochrane Library, 2006, , CD001938.	1.5	26
100	Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection. Journal of the National Cancer Institute, 2006, 98, 996-1004.	3.0	237
101	The Methodologic Ozone Effect. Epidemiology, 2005, 16, 430-435.	1.2	8
102	Introduction to Bayesian methods I: measuring the strength of evidence. Clinical Trials, 2005, 2, 282-290.	0.7	123
103	Ethics and evidence in clinical trials. Clinical Trials, 2005, 2, 195-196.	0.7	6
104	A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barre. Clinical Trials, 2005, 2, 305-310.	0.7	39
105	Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2005, 11, 8413-8417.	3.2	9
106	Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16368-16373.	3.3	1,049
107	Role and limitations of epidemiology in establishing a causal association. Seminars in Cancer Biology, 2004, 14, 413-426.	4.3	25
108	Catalytic Asymmetric Total Syntheses of Quinine and Quinidine. Journal of the American Chemical Society, 2004, 126, 706-707.	6.6	170

#	Article	IF	Citations
109	Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimerâ€™s Disease: A Systematic Review. Neuroepidemiology, 2004, 23, 159-169.	1.1	369
110	Toward protecting the safety of participants in clinical trials. Contemporary Clinical Trials, 2003, 24, 256-271.	2.0	56
111	Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies. Journal of the National Cancer Institute, 2003, 95, 1634-1637.	3.0	110
112	Commentary: The P-value, devalued. International Journal of Epidemiology, 2003, 32, 699-702.	0.9	19
113	The Mammography Dilemma. Annals of Internal Medicine, 2003, 138, 771.	2.0	2
114	Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clinical Cancer Research, 2003, 9, 1370-5.	3.2	120
115	How Statistical Expertise Is Used in Medical Research. JAMA - Journal of the American Medical Association, 2002, 287, 2817.	3.8	104
116	Acne therapy: A methodologic review. Journal of the American Academy of Dermatology, 2002, 47, 231-240.	0.6	148
117	Enantiopure Î²-Hydroxy Morpholine Amides from Terminal Epoxides by Carbonylation at 1 atm. Angewandte Chemie - International Edition, 2002, 41, 4703-4705.	7.2	62
118	Prevention of thromboembolism in atrial fibrillation. Journal of General Internal Medicine, 2000, 15, 56-67.	1.3	108
119	Bayesian Communication: A Clinically Significant Paradigm for Electronic Publication. Journal of the American Medical Informatics Association: JAMIA, 2000, 7, 254-266.	2.2	16
120	Very high risk of cancer in familial Peutzâ€“Jeghers syndrome. Gastroenterology, 2000, 119, 1447-1453.	0.6	1,247
121	Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy. Annals of Internal Medicine, 1999, 130, 995.	2.0	935
122	Toward Evidence-Based Medical Statistics. 2: The Bayes Factor. Annals of Internal Medicine, 1999, 130, 1005.	2.0	732
123	Probability at the Bedside: The Knowing of Chances or the Chances of Knowing?. Annals of Internal Medicine, 1999, 130, 604.	2.0	46
124	Letter to the Editor: Bayesian analysis for a single 2Ã—2 table by L. Hashemi, B. Nandram and R. Goldberg,Statistics in Medicine,16, 1311-1328 (1997). , 1998, 17, 2147-2148.		0
125	Statistical reviewing policies of medical journals. Journal of General Internal Medicine, 1998, 13, 753-756.	1.3	93
126	What Patients Say about Medical Research. IRB: Ethics & Human Research, 1998, 20, 1.	0.8	87

#	Article	IF	Citations
127	What patients say about medical research. IRB: Ethics & Human Research, 1998, 20, 1-7.	0.8	25
128	Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Human Pathology, 1996, 27, 119-124.	1.1	186
129	Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients. Annals of Surgery, 1995, 221, 721-733.	2.1	884
130	Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine, 1995, 14, 1149-1161.	0.8	457
131	Future prospects discussed. Nature, 1994, 368, 106-107.	13.7	9
132	The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results. Annals of Internal Medicine, 1994, 121, 200.	2.0	543
133	Manuscript Quality before and after Peer Review and Editing at Annals of Internal Medicine. Annals of Internal Medicine, 1994, 121, 11.	2.0	252
134	p Values, Hypothesis Tests, and Likelihood: Implications for Epidemiology of a Neglected Historical Debate. American Journal of Epidemiology, 1993, 137, 485-496.	1.6	285
135	A comment on replication,P-values and evidence. Statistics in Medicine, 1992, 11, 875-879.	0.8	260
136	One-sided or two-sided p values?. Contemporary Clinical Trials, 1988, 9, 387-388.	2.0	4